Spectrum of Activity


General Information

  • For the treatment of herpes zoster (shingles)
  • For the treatment or suppression of genital herpes in immunocompetent individuals and for the suppression of recurrent genital herpes in HIV infected individuals
  • To reduce the risk of transmission of genital herpes with the use of suppressive therapy
  • For the treatment of cold sores (herpes labialis)
  • Headache
  • Nausea
  • Acute kidney injury
  • Increased AST and ALT
  • CNS effects (agitation, hallucinations, confusion and encephalopathy)
  • Thrombotic Thrombocytopenia Purpura/Hemolytic Uremic Syndrome (TTP/HUS)
  • No clinically significant interactions have been identified. Screen drug specific interactions for interactions via CYP 1A2 and pharmacodynimc adverse effects
  • Increased risk of nephrotoxicity when used concomitantly with other nephrotoxic agents
  • Tablets can be crushed for NG administration
  • No liquid formulation available
  • ValACYclovir is a prodrug of the antiviral acyclovir
  • ValACYclovir is rapidly and nearly completely converted to acyclovir